Ponatinib Hydrochloride API Suppliers & Bulk Manufacturers
Available Forms: API (drug substance)
Available Strengths: USP grade or in-house specification
Reference Brands: Iclusig
Category: Active Pharmaceutical Ingredient
Ponatinib hydrochloride is a potent BCR-ABL kinase inhibitor used in oral leukaemia products. It is sourced by oncology formulators, CDMOs and R&D teams.
Manufacture or export Ponatinib Hydrochloride API? List it or send an offer →
Product Description:
Ponatinib is a tyrosine kinase inhibitor that blocks BCR-ABL, including the T315I mutant form that resists other inhibitors in this class. It is approved for certain adults with chronic myeloid leukaemia in chronic, accelerated or blast phase, including T315I-positive disease, and for Philadelphia chromosome-positive acute lymphoblastic leukaemia; in the US this includes newly diagnosed disease in combination with chemotherapy (reference brand: Iclusig).
Specification at a glance
| Traded form | Monohydrochloride salt; several solid forms are described, so the crystal form should match the intended formulation |
|---|---|
| CAS number | 1114544-31-8 |
| Molecular formula | C29H28ClF3N6O |
| Molecular weight | 569.0 g/mol |
| Pharmacopoeia | No pharmacopoeia monograph found. Ponatinib hydrochloride was on the USP priority list for new monographs in 2024, so no official USP monograph was available then; supplied to an in-house specification. |
Regulatory files and timing
The FDA list of Drug Master Files (third quarter 2026) shows 4 active Type II API DMFs for this molecule. Few filings usually means few qualified sources, so early contact with suppliers pays off. For Europe, ask whether the supplier holds a CEP or an EU ASMF and, for imports into the EU, a written confirmation.
Generic or biosimilar entry. United States: Patent expiry; entry not confirmed (Jan 2027). European Union: No confirmed date.
Handling and quality points
Ponatinib is a potent kinase inhibitor with reproductive and cardiovascular toxicity, so most makers handle it under high-potency containment with closed transfers and verified cleaning. The hydrochloride exists in more than one solid form, so confirm the polymorph by XRPD and check that it stays stable under your processing conditions. The N-methylpiperazine part of the molecule means a nitrosamine risk assessment is expected, alongside control of mutagenic impurities from the coupling steps.
Send an API enquiry All specialty APIs
Brand names are trademarks of their respective owners and identify the reference medicine only. Information is general and was checked in October 2026; confirm specifications and filings with the supplier before purchase.
Ponatinib Hydrochloride API — third party manufacturing & bulk supply
Ponatinib Hydrochloride API is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Ponatinib Hydrochloride API is supplied as API (drug substance) — a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Ponatinib Hydrochloride API listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Ponatinib Hydrochloride API →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Buyers usually ask for the GMP certificate, a US DMF letter of access or EU ASMF, a CoA with XRPD and related substances, and long-term stability data. A nitrosamine risk assessment and an ICH M7 mutagenic impurity assessment are now standard requests for this molecule. Containment and occupational exposure information is useful if you plan to handle it on a shared line.
Ponatinib hydrochloride has several known polymorphs and solvates, and the form affects dissolution and stability. Specify the form used in your formulation development and ask the supplier for XRPD, DSC and water sorption data, along with evidence that the form does not convert on storage. Also check any patent position covering the form in your target market.
Yes. We help licensed formulation companies, CDMOs and research groups reach GMP-compliant ponatinib hydrochloride producers. PharmaTradz looks over the supplier's documents first, and nobody sees your company details until both parties agree.
Related Products
Nusinersen Sodium API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Spinraza
View DetailsLinaclotide API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Linzess, Constella
View DetailsTrabectedin API
Strength:
USP grade or in-house specification
Form: API (drug substance)
Reference Brands: Yondelis
View DetailsLetermovir API
Strength:
USP grade or in-house specification
Form: API (drug substance)
Reference Brands: Prevymis
View DetailsEntecavir API
Strength:
Supplied as high-purity crystals in 99%
Form: White to off-white crystalline powder
Reference Brands: Baraclude (US/EU)
View DetailsMagnesium Hydroxide
Strength:
Purity: ≥ 98% (on dry basis)
Form: White, odorless powder
Reference Brands:
View DetailsRucaparib Camsylate
Strength:
Purity: ≥ 99% (HPLC, on anhydrous basis)
Form: Granules/ Powder
Reference Brands:
View DetailsDulaglutide
Strength:
Purity: ≥ 98% (HPLC)/Peptide content: As Dulaglutide base
Form: White to off-white lyophilized powder (peptide API)
Reference Brands: Trulicity (US/EU)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit